Metabolic complications of protease inhibitors: what have we learned so far?
Erbelding
E J
EJ
D002641:Chicago; D003226:Congresses as Topic; D003327:Coronary Disease / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D018149:Glucose Intolerance / Q000139:chemically induced; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000378:metabolism*; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D008060:Lipodystrophy / Q000139:chemically induced*
D017320:HIV Protease Inhibitors